RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Coherus BioSciences Stock

Coherus BioSciences EBIT 2024

Coherus BioSciences EBIT

-90.91 M USD

Ticker

CHRS

ISIN

US19249H1032

WKN

A12ETZ

In 2024, Coherus BioSciences's EBIT was -90.91 M USD, a -54.15% increase from the -198.3 M USD EBIT recorded in the previous year.

The Coherus BioSciences EBIT history

YEAREBIT (undefined USD)
2030e1.26
2029e1.2
2028e0.12
2027e0.13
2026e0
2025e-0.06
2024e-0.09
2023-0.2
2022-0.26
2021-0.26
20200.16
20190.11
2018-0.2
2017-0.23
2016-0.12
2015-0.22
2014-0.06
2013-0.04
2012-0.04

Coherus BioSciences Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Coherus BioSciences, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Coherus BioSciences from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Coherus BioSciences’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Coherus BioSciences. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Coherus BioSciences’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Coherus BioSciences’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Coherus BioSciences’s growth potential.

Coherus BioSciences Revenue, EBIT and net profit per share

DateCoherus BioSciences RevenueCoherus BioSciences EBITCoherus BioSciences Net Income
2030e1.55 B undefined1.26 B undefined683.35 M undefined
2029e618.29 M undefined1.2 B undefined132.79 M undefined
2028e559.12 M undefined115.83 M undefined111.25 M undefined
2027e510.24 M undefined132.28 M undefined113.99 M undefined
2026e354.61 M undefined1.37 M undefined10.97 M undefined
2025e316.21 M undefined-56.14 M undefined-30.69 M undefined
2024e270.58 M undefined-90.91 M undefined-113.69 M undefined
2023257.24 M undefined-198.3 M undefined-237.89 M undefined
2022211 M undefined-256.9 M undefined-291.8 M undefined
2021326.6 M undefined-263.9 M undefined-287.1 M undefined
2020475.8 M undefined156.3 M undefined132.2 M undefined
2019356.1 M undefined107.8 M undefined89.8 M undefined
20180 undefined-204.4 M undefined-209.3 M undefined
20171.6 M undefined-232.1 M undefined-238.2 M undefined
2016190.1 M undefined-115.9 M undefined-127.3 M undefined
201530 M undefined-219.1 M undefined-223.3 M undefined
201431.1 M undefined-64.7 M undefined-87.1 M undefined
20132.8 M undefined-36 M undefined-53.6 M undefined
20121.9 M undefined-38.5 M undefined-33 M undefined

Coherus BioSciences stock margins

The Coherus BioSciences margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Coherus BioSciences. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Coherus BioSciences.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Coherus BioSciences's sales revenue. A higher gross margin percentage indicates that the Coherus BioSciences retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Coherus BioSciences's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Coherus BioSciences's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Coherus BioSciences's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Coherus BioSciences. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Coherus BioSciences's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Coherus BioSciences Margin History

Coherus BioSciences Gross marginCoherus BioSciences Profit marginCoherus BioSciences EBIT marginCoherus BioSciences Profit margin
2030e38.19 %81.31 %44.03 %
2029e38.19 %193.92 %21.48 %
2028e38.19 %20.72 %19.9 %
2027e38.19 %25.93 %22.34 %
2026e38.19 %0.39 %3.09 %
2025e38.19 %-17.76 %-9.71 %
2024e38.19 %-33.6 %-42.02 %
202338.19 %-77.09 %-92.48 %
202266.82 %-121.75 %-138.29 %
202182.36 %-80.8 %-87.91 %
202092.1 %32.85 %27.78 %
201995.2 %30.27 %25.22 %
201838.19 %0 %0 %
201738.19 %-14,506.25 %-14,887.5 %
201638.19 %-60.97 %-66.96 %
201538.19 %-730.33 %-744.33 %
201438.19 %-208.04 %-280.06 %
201338.19 %-1,285.71 %-1,914.29 %
201238.19 %-2,026.32 %-1,736.84 %

Coherus BioSciences Aktienanalyse

What does Coherus BioSciences do?

Coherus BioSciences Inc is a pharmaceutical company specializing in the development and marketing of biosimilars. The company was founded in California in 2010 and has since focused on the development of biopharmaceuticals. Coherus BioSciences Inc's history began with the acquisition of the biomanufacturing facility from PDL BioPharma, a company specialized in the development and marketing of therapeutics and biologics. Coherus BioSciences Inc used the facility to build a portfolio of biosimilars. Coherus BioSciences Inc's business model is based on the sale of biosimilars, which offer a cost-effective alternative to expensive biologics. Biosimilars are biopharmaceuticals that are manufactured similarly to already approved biologics, but can be offered at a lower price. Coherus BioSciences Inc specializes in the development and marketing of biosimilars in the fields of oncology, immunology, and neurology. The products that the company currently brings to market or is developing include biosimilar versions of Enbrel, Neulasta, and Humira. Enbrel is a biologic used to treat rheumatoid arthritis, psoriasis, and other inflammatory conditions. Neulasta is a medication used to support white blood cells after chemotherapy, while Humira is a medication used to treat autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and psoriasis. Coherus BioSciences Inc has also launched a collaboration with Novartis to develop a biosimilar version of Lucentis. Lucentis is a biologic used to treat age-related macular degeneration. Overall, Coherus BioSciences Inc has built a portfolio of ten biosimilars and is working to bring more products to market. The company has also conducted several preclinical and clinical studies to demonstrate the efficacy and safety of its biosimilars. Coherus BioSciences Inc is headquartered in Redwood City, California. The company currently employs over 140 employees and has offices in the USA, Europe, and Asia. Overall, Coherus BioSciences Inc has played a groundbreaking role in the development of cost-effective biosimilars. The company specializes in the marketing of biosimilars and offers a range of products in the fields of oncology, immunology, and neurology. Coherus BioSciences Inc has also launched a collaboration with another company to develop a biosimilar version of Lucentis. The company has built a portfolio of ten biosimilars and is constantly expanding its offerings. Coherus BioSciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Coherus BioSciences's EBIT

Coherus BioSciences's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Coherus BioSciences's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Coherus BioSciences's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Coherus BioSciences’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Coherus BioSciences stock

How much did Coherus BioSciences achieve in EBIT for the current year?

In the current year, Coherus BioSciences has achieved an EBIT of -90.91 M USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Coherus BioSciences.

How has the EBIT of Coherus BioSciences developed in recent years?

The EBIT of Coherus BioSciences has increased by -54.153% decreased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Coherus BioSciences?

The EBIT of Coherus BioSciences is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Coherus BioSciences pay?

Over the past 12 months, Coherus BioSciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Coherus BioSciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Coherus BioSciences?

The current dividend yield of Coherus BioSciences is .

When does Coherus BioSciences pay dividends?

Coherus BioSciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Coherus BioSciences?

Coherus BioSciences paid dividends every year for the past 0 years.

What is the dividend of Coherus BioSciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Coherus BioSciences located?

Coherus BioSciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Coherus BioSciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Coherus BioSciences from 10/15/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/15/2024.

When did Coherus BioSciences pay the last dividend?

The last dividend was paid out on 10/15/2024.

What was the dividend of Coherus BioSciences in the year 2023?

In the year 2023, Coherus BioSciences distributed 0 USD as dividends.

In which currency does Coherus BioSciences pay out the dividend?

The dividends of Coherus BioSciences are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Coherus BioSciences stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Coherus BioSciences

Our stock analysis for Coherus BioSciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Coherus BioSciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.